Reported Earlier, Pliant Therapeutics Presented Bexotegrast Program Data At American Thoracic Society 2024 International Conference

Author: Benzinga Newsdesk | May 22, 2024 03:51am

In an oral presentation, Gregory P. Cosgrove, M.D., FCCP, Vice President of Clinical Development at Pliant Therapeutics provided an integrated safety and tolerability analysis of bexotegrast across completed studies with unblinded data, including those conducted in healthy volunteers and in patients with idiopathic pulmonary fibrosis (IPF) or primary sclerosing cholangitis (PSC). To date, in unblinded and blinded studies, bexotegrast has been administered to over 700 participants. Across 11 Phase 1 and 4 Phase 2 trials, bexotegrast was well tolerated, most treatment-emergent adverse events being mild to moderate with trial participants experiencing low drug discontinuation rates.

Posted In: PLRX